USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Bayer Pharma Aktiengesellschaft

USPTO PatentsView assignee record — 326 granted patents across 33 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

326
Total patents granted
33
CPC technology areas
14.9
Avg claims per patent
-16%
5-year filing velocity

Portfolio overview

Bayer Pharma Aktiengesellschaft has been granted 326 US utility patents between 2015 and 2025, placing Bayer Pharma Aktiengesellschaft at rank #1,295 across all assignees tracked by PlainPatent. This portfolio spans 33 distinct Cooperative Patent Classification (CPC) subclasses, averaging 14.9 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Bayer Pharma Aktiengesellschaft is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 53.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 149 grants, compared with 177 in the 2015–2019 window — a -16% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Bayer Pharma Aktiengesellschaft's 14.9 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 33 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Bayer Pharma Aktiengesellschaft against peers pursuing similar technology classes.

How does Bayer compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows Bayer holds 326 patents — placing it at rank #1,295 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

USPTO utility patent grants by year · 2015–2025

0102030405060 20152016201720182019202020212022202320242025 7
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Bayer Pharma Aktiengesellschaft patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 5 1.5%
2016 32 9.8%
2017 47 14.4%
2018 44 13.5%
2019 49 15.0%
2020 30 9.2%
2021 37 11.3%
2022 33 10.1%
2023 22 6.7%
2024 20 6.1%
2025 7 2.1%

Patent Moat Analysis

Portfolio Volume Moderate
Tech Breadth Multi-domain
Claim Depth Standard
Velocity Declining

Where it ranks

Overall rank by patents

#1,295

Across all tracked assignees

Innovation Score

53.6 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Bayer Pharma Aktiengesellschaft hold?
Bayer Pharma Aktiengesellschaft holds 326 US granted patents filed between 2015 and 2025, spanning 33 technology areas.
What is Bayer Pharma Aktiengesellschaft's Innovation Score?
Bayer Pharma Aktiengesellschaft has an Innovation Score of 53.6 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Bayer Pharma Aktiengesellschaft focus on?
Bayer Pharma Aktiengesellschaft's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 289 patents. The company has filed patents in 33 CPC subclasses total.
Is Bayer Pharma Aktiengesellschaft's patent filing rate increasing or decreasing?
Bayer Pharma Aktiengesellschaft's recent filing velocity is -16% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Bayer Pharma Aktiengesellschaft's patents?
Bayer Pharma Aktiengesellschaft's patents average 14.9 claims each. This falls within the standard range, providing solid legal coverage.
How is the Bayer Pharma Aktiengesellschaft patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

Explore the patent dataset

Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

All federal data sources used on this page
  • USPTO PatentsView — official U.S. Patent and Trademark Office bulk patent data. patentsview.org
  • USPTO Patent Application Information Retrieval (PAIR) — application status and file history. uspto.gov/patents/pair
  • USPTO Bulk Data Storage System — comprehensive patent text + claims dataset. bulkdata.uspto.gov
  • USPTO CPC Classification — Cooperative Patent Classification scheme for technology categorization. uspto.gov/cpc
  • SEC EDGAR — public filings cross-reference for assignee corporate entity matching. sec.gov/edgar
  • WIPO PATENTSCOPE — international patent context (related international filings). wipo.int/patentscope